Anavex Life Sciences Corp (AVXL)

[Franz1969]

Summary from presentation deck:

ANAVEX®2-73 treatment slowed decline of cognition and function in patients with early Alzheimer’s
disease over 48 weeks
• Patients on ANAVEX®2-73 treatment were 84% more likely to improve cognitively compared to placebo,
by ADAS-Cog score threshold change of -0.50 points or better
• ANAVEX®2-73 treatment slowed cognitive decline by 45% compared to placebo at 48 weeks
• At clinically significant levels of improvement in function (ADCS-ADL score threshold change of +3.5
points or better), ANAVEX®2-73 treatment was 167% more likely to improve function compared to
placebo
• Compared to placebo, ANAVEX®2-73 reduced clinical decline of cognition and function by 27% as
measured by the CDR-SB
• ANAVEX®2-73 was safe and well tolerated